Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol Beier J; Beeh KMInt J Chron Obstruct Pulmon Dis 2011[]; 6 (ä): 237-43Bronchodilators are the cornerstone of severe chronic obstructive pulmonary disease (COPD) treatment to improve airflow, symptoms, exercise tolerance, and exacerbations. There is convincing evidence that regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators. Long-acting beta-2-agonists include the twice-daily drugs formoterol and salmeterol and, more recently, once-daily indacaterol. Studies with head-to-head comparisons of long-acting bronchodilators are scant, but novel data from controlled trials with the once-daily beta(2)-agonist indacaterol indicate superior bronchodilation and clinical efficacy of indacaterol at recommended doses over twice-daily long-acting beta(2)-agonists, and at least equipotent bronchodilation compared with once-daily tiotropium. The recent therapeutic developments in COPD underscore a shift from short-acting bronchodilators with multiple dosings per day to reduced dosing frequency and prolonged duration of action, including once-daily treatment, with more consistent effects on various clinical outcomes. This review summarizes relevant clinical data for twice-daily beta-2-agonists in COPD, and further focuses on novel data for once-daily indacaterol, including head-to-head comparison trials.|Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects/*therapeutic use[MESH]|Bronchodilator Agents/administration & dosage/adverse effects/*therapeutic use[MESH]|Drug Administration Schedule[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Indans/administration & dosage/adverse effects/*therapeutic use[MESH]|Lung/*drug effects/physiopathology[MESH]|Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology[MESH]|Quinolones/administration & dosage/adverse effects/*therapeutic use[MESH]|Treatment Outcome[MESH] |